Prostate Cancer and Reactive Haemophagocytic Lymphohistiocytosis.
Auteurs : Dumont L, Salaroli A, Dal Lago L, Gil T, Pepersack T Année : 2021 Journal : Eur J Case Rep Intern Med
Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer.
Auteurs : Martinez Chanza N, Bernard B, Barthelemy P, Accarain A, Paesmans M, Desmyter L, Tkint de Roodenbeke D, Gil T, Sideris S, Roumeguere T, Hamid AA, Sweeney CJ Année : 2021 Journal : Prostate Cancer Prostatic Dis
Oligometastatic Disease Detection with <sup>68</sup>Ga-PSMA-11 PET/CT in Hormone-Sensitive Prostate Cancer Patients (HSPC) with Biochemical Recurrence after Radical Prostatectomy: Predictive Factors and Clinical Impact.
Auteurs : Artigas C, Diamand R, Shagera QA, Plouznikoff N, Fokoue F, Otte FX, Gil T, Peltier A, Van Gestel D, Flamen P Année : 2021 Journal : Cancers (Basel)
<sup>68</sup>Ga-PSMA PET/CT for response assessment and outcome prediction in metastatic prostate cancer patients treated with taxane-based chemotherapy.
Auteurs : Shagera QA, Artigas C, Karfis I, Critchi G, Martinez Chanza N, Sideris S, Peltier A, Paesmans M, Gil T, Flamen P Année : 2021 Journal : J Nucl Med
An update on the management of metastatic clear-cell renal cell carcinoma: the BSMO Expert panel recommendations
Auteurs : Delafontaine B, De Backer D, Beuselinck B, Debruyne P, DHondt L, Gennigens C, Gil T, Vulsteke C, Martinez Chanza N, Verbiest A, Strijbos M, Van Lancker G, Pelgrims G, Rottey S Année : 2020 Journal : Belgian J Medical Oncology